Logo do repositório
 
Publicação

Strategies to enhance the response of liver cancer to pharmacological treatments

2024Artigo científico Acesso restrito
Ver registo simples
dc.contributor.authorMarin, Jose J.G.
dc.contributor.authorMacias, Rócio I.R.
dc.contributor.authorAsensio, Maitane
dc.contributor.authorRomero, Marta R.
dc.contributor.authorTemprano, Alvaro G.
dc.contributor.authorPereira, Olívia R.
dc.contributor.authorJimenez, Silvia
dc.contributor.authorMauriz, Jose Luis
dc.contributor.authorDi Giacomo, Silvia
dc.contributor.authorAvila, Matias A.
dc.contributor.authorEfferth, Thomas
dc.contributor.authorBriz, Oscar
dc.date.accessioned2024-07-22T11:07:30Z
dc.date.available2024-07-22T11:07:30Z
dc.date.issued2024
dc.description.abstractIn contrast to other types of cancers, there is no available efficient pharmacological treatment to improve the outcomes of patients suffering from major primary liver cancers, i.e., hepatocellular carcinoma and cholangiocarcinoma. This dismal situation is partly due to the existence in these tumors of many different and synergistic mechanisms of resistance, accounting for the lack of response of these patients, not only to classical chemotherapy but also to more modern pharmacological agents based on the inhibition of tyrosine kinase receptors (TKIs) and the stimulation of the immune response against the tumor using immune checkpoint inhibitors (ICIs). This review summarizes the effort to develop strategies to overcome this severe limitation, including searching for novel drugs derived from synthetic, semisynthetic, or natural products with vectorial properties against therapeutic targets to increase drug uptake or reduce drug export from cancer cells. Besides, immunotherapy is a promising line of research that is already starting to be implemented in clinical practice. Although less successful than in other cancers, the foreseen future for this strategy in treating liver cancers is considerable. Similarly, the pharmacological inhibition of epigenetic targets is highly promising. Many novel "epidrugs", able to act on "writer", "reader" and "eraser" epigenetic players, are currently being evaluated in preclinical and clinical studies. Finally, gene therapy is a broad field of research in the fight against liver cancer chemoresistance, based on the impressive advances recently achieved in gene manipulation. In sum, although the present is still dismal, there is reason for hope in the non-too-distant future.pt_PT
dc.description.sponsorshipThis study received funding from various sources, including the CIBERehd under Grant Nos. EHD15PI05 and EHD22PI01 and Fondo de Investigaciones Sanitarias, Instituto de Salud Carlos III, Spain, cofunded by the European Regional Development Fund/European Social Fund, “Investing in your future” under Grant Nos. PI19/00819, PI20/00189, PI22/00526, and PI23/00681; “Junta de Castilla y Leon” under Grant Nos. SA074P20, SA113P23, and GRS 2322/A/21; Fundacio La Marato TV3 under Grant No. Ref. 201916-31, Spain; University of Salamanca under Grant Nos. PIC2-2021-11 and PC_TCUE21-23_011, Spain; and AECC Scientific Foundation PRYCO223102ARM under Grant No. 2023/2027, Spain. Plan Estatal de Investigacion Científica y Tecnica y Innovacion, cofinanciado con Fondos FEDER PID2020-119164RB-I00, PID2022-136616OB-I00, and PID2022-140210OB-I00 funded by MCIN/AEI/10.13039/ 501100011033; ERA-NET TRANSCAN-3 project TRANSCAN2022-784-024. Fundacion Espanola para el Estudio del Hígado (FEEH), Juan Cordoba Fellowship, Grant 2021, Spain. FCT/MCTES (PIDDAC): CIMO, UIDB/00690/2020 (DOI: 10.54499/UIDB/00690/2020) and UIDP/00690/2020 (DOI: 10.54499/UIDP/00690/2020); and SusTEC, LA/P/0007/2020 (DOI: 10.54499/LA/P/0007/2020), Portugal. This publication is based upon work from COST Action Precision-BTC-Network CA22125, supported by COST (European Cooperation in Science and Technology; www.cost.eu).pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationMarin, Jose J.G.; Macias, Rocio I.R.; Asensio, Maitane; Romero, Marta R.; Temprano, Alvaro G.; Pereira, Olívia R.; Jimenez, Silvia; Mauriz, Jose Luis; Di Giacomo, Silvia; Avila, Matias A.; Efferth, Thomas; Briz, Oscar (2024). Strategies to enhance the response of liver cancer to pharmacological treatments. American Journal of Physiology - Cell Physiology. ISSN 0363-6143. 327: 1, p. C11-C33pt_PT
dc.identifier.doi10.1152/ajpcell.00176.2024pt_PT
dc.identifier.eissn1522-1563
dc.identifier.issn0363-6143
dc.identifier.urihttp://hdl.handle.net/10198/30051
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherAmerican Physiological Societypt_PT
dc.relationMountain Research Center
dc.relationMountain Research Center
dc.relationAssociate Laboratory for Sustainability and Tecnology in Mountain Regions
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/pt_PT
dc.subjectABC proteinspt_PT
dc.subjectChemoresistancept_PT
dc.subjectCholangiocarcinomapt_PT
dc.subjectHepatocellular carcinomapt_PT
dc.subjectMultidrug resistancept_PT
dc.titleStrategies to enhance the response of liver cancer to pharmacological treatmentspt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.awardNumberUIDB/00690/2020
oaire.awardNumberUIDP/00690/2020
oaire.awardNumberLA/P/0007/2020
oaire.awardTitleMountain Research Center
oaire.awardTitleMountain Research Center
oaire.awardTitleAssociate Laboratory for Sustainability and Tecnology in Mountain Regions
oaire.awardURIinfo:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UIDB%2F00690%2F2020/PT
oaire.awardURIinfo:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UIDP%2F00690%2F2020/PT
oaire.awardURIinfo:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/LA%2FP%2F0007%2F2020/PT
oaire.citation.endPageC33pt_PT
oaire.citation.startPageC11pt_PT
oaire.citation.titleAmerican Journal of Physiology - Cell Physiologypt_PT
oaire.citation.volume327pt_PT
oaire.fundingStream6817 - DCRRNI ID
oaire.fundingStream6817 - DCRRNI ID
oaire.fundingStream6817 - DCRRNI ID
person.familyNamePereira
person.givenNameOlívia R.
person.identifier145216
person.identifier.ciencia-idB312-AF21-D2FA
person.identifier.orcid0000-0002-6275-3134
person.identifier.ridH-1049-2014
person.identifier.scopus-author-id52264387000
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.nameFundação para a Ciência e a Tecnologia
project.funder.nameFundação para a Ciência e a Tecnologia
project.funder.nameFundação para a Ciência e a Tecnologia
rcaap.rightsrestrictedAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublicatione8fdab9a-3ad6-47e6-b90c-7a37aabcb453
relation.isAuthorOfPublication.latestForDiscoverye8fdab9a-3ad6-47e6-b90c-7a37aabcb453
relation.isProjectOfPublication29718e93-4989-42bb-bcbc-4daff3870b25
relation.isProjectOfPublication0aac8939-28c2-46f4-ab6b-439dba7f9942
relation.isProjectOfPublication6255046e-bc79-4b82-8884-8b52074b4384
relation.isProjectOfPublication.latestForDiscovery6255046e-bc79-4b82-8884-8b52074b4384

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
ACELC-00176-2024 (00000002).pdf
Tamanho:
2.03 MB
Formato:
Adobe Portable Document Format
Ver/Abrir
Licença
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
license.txt
Tamanho:
1.75 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Ver/Abrir

Coleções

CIMO - Artigos em Revistas Indexados à WoS/Scopus